美国旧金山HIV治疗中断研究的参与者视角。

IF 1.1 4区 医学 Q4 IMMUNOLOGY
Elizabeth Nguyen, Anastasia Korolkova, Ali Ahmed, Steven Meanley, Lynda Dee, Maryam Hussain, Fang Wan, Rebecca Hoh, Antonio Rodriguez, Tony Figueroa, Lillian B Cohn, Steven G Deeks, Michael J Peluso, Shadi Eskaf, Jeremy Sugarman, John A Sauceda, Karine Dubé
{"title":"美国旧金山HIV治疗中断研究的参与者视角。","authors":"Elizabeth Nguyen, Anastasia Korolkova, Ali Ahmed, Steven Meanley, Lynda Dee, Maryam Hussain, Fang Wan, Rebecca Hoh, Antonio Rodriguez, Tony Figueroa, Lillian B Cohn, Steven G Deeks, Michael J Peluso, Shadi Eskaf, Jeremy Sugarman, John A Sauceda, Karine Dubé","doi":"10.1177/08892229251375470","DOIUrl":null,"url":null,"abstract":"<p><p>HIV cure-related clinical research studies often include analytical treatment interruptions (ATIs), in which participants pause antiretroviral treatment (ART). During ATIs, researchers closely monitor laboratory values and adverse events. We assessed and compared the perspectives of two distinct groups of participants: HIV noncontrollers and controllers in a San Francisco-based ATI study focused on identifying biomarkers predicting HIV viral rebound. Data were collected from 2021 to 2024 over five study time points to assess motivations, understanding of the study, decisional regret, and partner protections. All participants (n = 16) endorsed the goal of helping advance HIV research as a motivator, about half were also driven by interest in their body's response to the ATI, and some indicated monetary compensation as a key motivator. Most participants (6 of 10 noncontrollers and 4 of 6 controllers) did not view personal health benefit as a primary study goal. All understood the option for an extended ATI if they had not met ART restart criteria after 28 days. At the study's onset, all sexually active participants (n = 14) were informed about the risk of transmission to sex partners and the need for partner protections during ATIs. Among noncontrollers, 2 of 5 reported using condoms, being abstinent or partner use of pre-exposure prophylaxis (PrEP) during sexual activity. Among controllers, 3 of 5 reported sexual activity: one with a partner on PrEP, one with a partner on ART, and one using other protection methods. Decisional regret about study participation, measured on a scale of 0-100, was low among both noncontrollers (range 1.67-13.57), and controllers (range 8.33-10) during the ATI, and remained low following it (noncontroller M = 5.07, SD = 4.52; controller M = 10.00, SD = 11.31). Participants generally understood the study, highlighted the need for partner protection support during ATI, and reported low decisional regret.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448951/pdf/","citationCount":"0","resultStr":"{\"title\":\"Participant Perspectives in an HIV Treatment Interruption Study in San Francisco, United States.\",\"authors\":\"Elizabeth Nguyen, Anastasia Korolkova, Ali Ahmed, Steven Meanley, Lynda Dee, Maryam Hussain, Fang Wan, Rebecca Hoh, Antonio Rodriguez, Tony Figueroa, Lillian B Cohn, Steven G Deeks, Michael J Peluso, Shadi Eskaf, Jeremy Sugarman, John A Sauceda, Karine Dubé\",\"doi\":\"10.1177/08892229251375470\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>HIV cure-related clinical research studies often include analytical treatment interruptions (ATIs), in which participants pause antiretroviral treatment (ART). During ATIs, researchers closely monitor laboratory values and adverse events. We assessed and compared the perspectives of two distinct groups of participants: HIV noncontrollers and controllers in a San Francisco-based ATI study focused on identifying biomarkers predicting HIV viral rebound. Data were collected from 2021 to 2024 over five study time points to assess motivations, understanding of the study, decisional regret, and partner protections. All participants (n = 16) endorsed the goal of helping advance HIV research as a motivator, about half were also driven by interest in their body's response to the ATI, and some indicated monetary compensation as a key motivator. Most participants (6 of 10 noncontrollers and 4 of 6 controllers) did not view personal health benefit as a primary study goal. All understood the option for an extended ATI if they had not met ART restart criteria after 28 days. At the study's onset, all sexually active participants (n = 14) were informed about the risk of transmission to sex partners and the need for partner protections during ATIs. Among noncontrollers, 2 of 5 reported using condoms, being abstinent or partner use of pre-exposure prophylaxis (PrEP) during sexual activity. Among controllers, 3 of 5 reported sexual activity: one with a partner on PrEP, one with a partner on ART, and one using other protection methods. Decisional regret about study participation, measured on a scale of 0-100, was low among both noncontrollers (range 1.67-13.57), and controllers (range 8.33-10) during the ATI, and remained low following it (noncontroller M = 5.07, SD = 4.52; controller M = 10.00, SD = 11.31). Participants generally understood the study, highlighted the need for partner protection support during ATI, and reported low decisional regret.</p>\",\"PeriodicalId\":7544,\"journal\":{\"name\":\"AIDS research and human retroviruses\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448951/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS research and human retroviruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/08892229251375470\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08892229251375470","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

与艾滋病毒治疗相关的临床研究通常包括分析性治疗中断(ATIs),其中参与者暂停抗逆转录病毒治疗(ART)。在ATIs期间,研究人员密切监测实验室值和不良事件。在一项基于旧金山的ATI研究中,我们评估并比较了两组不同参与者的观点:HIV非控制者和控制者,该研究专注于识别预测HIV病毒反弹的生物标志物。从2021年到2024年,在五个研究时间点收集数据,以评估动机、对研究的理解、决策后悔和伴侣保护。所有参与者(n = 16)都赞同将帮助推进艾滋病毒研究作为一种激励因素,大约一半的参与者也对他们的身体对ATI的反应感兴趣,一些人表示货币补偿是一个关键的激励因素。大多数参与者(10名非控制者中的6名和6名控制者中的4名)没有将个人健康益处视为主要研究目标。所有人都明白,如果他们在28天后没有达到ART重新开始的标准,可以选择延长ATI。在研究开始时,所有性活跃的参与者(n = 14)都被告知传播给性伴侣的风险以及在ATIs期间伴侣保护的必要性。在非控制者中,五分之二的人报告在性行为中使用避孕套,禁欲或伴侣使用暴露前预防(PrEP)。在控制者中,5人中有3人报告有性行为:1人与伴侣使用预防措施,1人与伴侣使用抗逆转录病毒治疗,1人使用其他保护方法。在ATI期间,非控制者(范围1.67-13.57)和控制者(范围8.33-10)对参与研究的决定后悔的评分范围为0-100,在ATI期间,非控制者(M = 5.07, SD = 4.52;控制者M = 10.00, SD = 11.31)对参与研究的决定后悔的评分较低,并且在ATI之后仍然很低(非控制者M = 5.07, SD = 4.52;参与者普遍理解这项研究,强调在ATI期间需要伴侣保护支持,并报告了低决策后悔。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Participant Perspectives in an HIV Treatment Interruption Study in San Francisco, United States.

HIV cure-related clinical research studies often include analytical treatment interruptions (ATIs), in which participants pause antiretroviral treatment (ART). During ATIs, researchers closely monitor laboratory values and adverse events. We assessed and compared the perspectives of two distinct groups of participants: HIV noncontrollers and controllers in a San Francisco-based ATI study focused on identifying biomarkers predicting HIV viral rebound. Data were collected from 2021 to 2024 over five study time points to assess motivations, understanding of the study, decisional regret, and partner protections. All participants (n = 16) endorsed the goal of helping advance HIV research as a motivator, about half were also driven by interest in their body's response to the ATI, and some indicated monetary compensation as a key motivator. Most participants (6 of 10 noncontrollers and 4 of 6 controllers) did not view personal health benefit as a primary study goal. All understood the option for an extended ATI if they had not met ART restart criteria after 28 days. At the study's onset, all sexually active participants (n = 14) were informed about the risk of transmission to sex partners and the need for partner protections during ATIs. Among noncontrollers, 2 of 5 reported using condoms, being abstinent or partner use of pre-exposure prophylaxis (PrEP) during sexual activity. Among controllers, 3 of 5 reported sexual activity: one with a partner on PrEP, one with a partner on ART, and one using other protection methods. Decisional regret about study participation, measured on a scale of 0-100, was low among both noncontrollers (range 1.67-13.57), and controllers (range 8.33-10) during the ATI, and remained low following it (noncontroller M = 5.07, SD = 4.52; controller M = 10.00, SD = 11.31). Participants generally understood the study, highlighted the need for partner protection support during ATI, and reported low decisional regret.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.10
自引率
6.70%
发文量
201
审稿时长
3-6 weeks
期刊介绍: AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes. AIDS Research and Human Retroviruses coverage includes: HIV cure research HIV prevention science - Vaccine research - Systemic and Topical PreP Molecular and cell biology of HIV and SIV Developments in HIV pathogenesis and comorbidities Molecular biology, immunology, and epidemiology of HTLV Pharmacology of HIV therapy Social and behavioral science Rapid publication of emerging sequence information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信